Publication of Inside Information according to Article 17 MAR
Epigenomics AG issues new shares by way of private placement
Not for distribution in the United States of America
Berlin, Germany, November 7, 2016 – Epigenomics AG, Berlin, Germany (Frankfurt Prime Standard: ECX, ISIN: DE0000A11QW50), announces that the Company is raising close to EUR 5.0 million of gross proceeds in a share capital increase by way of private placement.
The Executive Board of Epigenomics AG, with approval of the Supervisory Board, has today resolved on the increase of the Company’s share capital in the amount of EUR 1,035,196.00 by issuing 1,035,196 new registered shares of the Company from the Authorized Capital 2016/I against contribution in cash. The issue price has been set at EUR 4.83 per share.
The majority of the capital increase was subscribed by UChip Technology Limited, a subsidiary of SummitView Capital, Shanghai (China) and the remaining shares are the continued participation of BioChain (BVI) Inc.
The new shares will be issued by way of a private placement with the exclusion of the shareholders’ pre-emptive rights and carry dividend rights from January 1, 2016.
Following the registration of the capital increase with the commercial register (“Handelsregister”), the subscribed capital of Epigenomics AG will increase from currently EUR 20,544,009.00 to EUR 21,579,205.00. Subject to the registration of the implementation of the capital increase with the commercial register, the admission of the new shares to the regulated market (prime standard), of the Frankfurt Stock Exchange is expected during November 2016. The technical implementation of the capital increase is conducted by Bankhaus Neelmeyer, Bremen, Germany.
Epigenomics AG intends to use the net proceeds from the offering to finance its current operations and to expand its U.S commercialization capacities for its lead product Epi proColon.
-End of Ad hoc-
Greg Hamilton, Chief Executive Officer of Epigenomics AG, commented: “I am very excited to welcome SummitView Capital as a new strategic investor, who has an impressive track record of investments into transformative companies. With this investment, we further strengthen our financial position, helping us in driving the commercialization of our lead product Epi proColon, the first and only FDA-approved blood-test for colorectal cancer screening.”
This publication is not an offer of any securities for sale or a solicitation of an offer to purchase any securities.
This document is not an offer of securities for sale or a solicitation of an offer to purchase securities in the United States. The shares of Epigenomics AG (the “Shares”) have not been registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) and may not be offered or sold in the United States unless registered under the Securities Act or pursuant to an exemption from such registration. There will be no public offering of the Shares in the United States and the Shares will not be registered under the Securities Act.
Contact Epigenomics AG
Vice President Corporate Communications & Investor Relations
Phone +49 (0) 30 24345 386